1. Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)? 
Marina Noris, PhD, Piero Ruggenenti, MD, Giuseppe Remuzzi, MD, FRCP 
American Journal of Kidney Diseases 
Volume 70, Issue 6, Pages (December 2017)
DOI: /j.ajkd
Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Posttransplantation outcome in patients with atypical hemolytic uremic syndrome who received a kidney transplant at the Renal Transplant Unit, ASST PG23, Bergamo, Italy, from 2014 to Patients received the following treatment: pretransplantation plasma exchange (1 volume fresh frozen plasma); induction therapy: basiliximab (20mg days 0 and 4 posttransplantation) and antithymocyte globulin (0.5mg/kg/d for 1 week); and maintenance immunosuppression: steroids (1 week), cyclosporine (starting dose, 3-5mg/kg/d, then tapering), mycophenolate mofetil (750mg twice daily), or azathioprine (75mg/d). No eculizumab prophylaxis was given. Gene variant: pathogenetic or likely pathogenetic variants in complement genes. Abbreviations: CFH, complement factor H; CFI, complement factor I; MCP, membrane cofactor protein; nd, no complement gene variant detected. Data from V. Portalupi (personal communication [July 24, 2017]) and 2 of the authors (P.R. and G.R.).
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions